Market Notice 148/19 – Information regarding the rights issue from PharmaLundensis AB

Pending decision at the extra general meeting June 11, the last day of trading in the company’s shares PHAL including the right to receive unit rights is June 11, 2019. The first day excluding the right to obtain the rights is June 12, 2019.

One (1) share entitles the owner to one (1) unit right. Twenty-two (22) unit rights entitle the owner to subscribe for one (1) new unit, at the price of SEK 6.00 (3:22 á SEK 6.00).  

Trading with unit rights will take place from June 17, 2019 until June 27, 2019 on Spotlight Stock Market.

Trading with the paid subscribed units will take place from June 17, 2019 until the registration of the issue at Bolagsverket.  

The subscription period lasts from June 17, 2019 to July 1, 2019.

Information about the unit right:  
Shortname: PHAL UR
ISIN-code: SE0012729846
Orderbook-ID: 591G
CFI: RSIXXR
FISN: PHARMALUND/SUBS RTS NL PD
First day of trading: June 17, 2019
Last day of trading: June 27, 2019
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Information about the paid subscribed unit:    
Shortname: PHAL BTU
ISIN-code: SE0012729853
Orderbook-ID: 591H
CFI: MCMUXR
FISN: PHARMALUND/UT 3 AK + 2 TO
Trading period: June 17, 2019 until the registration of the issue at Bolagsverket.
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Please be advised that if the rights issue give rise to a conversion factor, all overnight orders in the company’s orderbook will be deleted. If so this will occur after closing on June 11, 2019. 

Stockholm June 10, 2019

Spotlight Stock Market
08-511 68 000
info@spotlightstockmarket.com 

Om oss

PharmaLundensis affärsidé är att utveckla nya och kreativa läkemedel mot sjukdomar som idag saknar effektiv behandling. En ny behandling mot den svåra lungsjukdomen KOL med IodoCarb® befinner sig i klinisk fas, och bolaget avser inom kort att starta kliniska studier mot fler svårbehandlade sjukdomar.

Prenumerera

Dokument & länkar